Occult hepatitis B virus coinfection in HIV-positive African migrants to the UK: A point prevalence study

HIV Medicine

Volumn 15, Issue 3, 2014, Pages 189-192

  Chadwick, D ^a   Doyle, T ^b   Ellis, S ^c   Price, D ^c   Abbas, I ^a   Valappil, M ^c   Geretti, Am ^b,d  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL VICTORIA INFIRMARY   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

African; HIV; Occult hepatitis B; Prevalence

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; MALE; MIDDLE AGED; MIXED INFECTION; NEGRO; PREVALENCE; PRIORITY JOURNAL; UNITED KINGDOM; VIRUS LOAD;

AFRICAN; HIV; OCCULT HEPATITIS B; PREVALENCE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANONYMOUS TESTING; COINFECTION; DNA, VIRAL; FEMALE; GREAT BRITAIN; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; RISK FACTORS; TRANSIENTS AND MIGRANTS; VIRAL LOAD;

EID: 84893728576     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12093     Document Type: Article

References (15)

1. Burnett RJ, François G, Kew MC. Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver Int 2005; 25: 201-213.
2. Geretti AM, Patel M, Sarfo FS etal. Detection of highly prevalent hepatitis B virus co-infection among HIV-seropositive persons in Ghana. J Clin Microbiol 2010; 48: 3223-3230.
3. Thio CL, Seaberg EC, Skolasky R Jr etal. Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926.
4. Law WP, Dore GJ, Duncombe CJ etal. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 2003; 17: 2191-2199.
5. Mphahlele MJ, Lukhwareni A, Burnett R etal. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 2006; 35: 14-20.
6. Firnhaber C, Viana R, Reyneke A etal. Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis 2009; 13: 488-492.
7. N'dri-Yoman T, Anglaret X, Messou E etal. Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire. Antivir Ther 2010; 15: 1029-1034.
8. Bloquel B, Jeulin H, Burty C etal. Occult hepatitis B infection in patients infected with HIV: report of two cases of hepatitis B reactivation and prevalence in a hospital cohort. J Med Virol 2010; 82: 206-212.
9. Morsica G, Ancarani F, Bagaglio S etal. Occult hepatitis B virus infection in a Cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features. Infection 2009; 37: 445-449.
10. Nebbia G, Garcia-Diaz A, Ayliffe U etal. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol 2007; 79: 1464-1471.
11. Shire NJ, Rouster SD, Stanford SD etal. The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2007; 44: 309-314.
12. Cacciola I, Pollicino T, Squadrito G etal. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-26.
13. Chadwick D, Stanley A, Sarfo S etal. Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa. AIDS 2013; 27: 139-141.
14. Chen CJ, Yang HI, Su J etal. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
15. Reuter S, Oette M, Wilhelm FC etal. Prevalence and characteristics of hepatitis B and C virus infections in treatment-nai{dotless}ve HIV-infected patients. Med Microbiol Immunol 2011; 200: 39-49.